IP Library Patent Application 13294911
Patent Application
App. No. 13/294,911

MINICELL BASED DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/294,911
Abstract

Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.

Claims (20)

1 . A fully intact eubacterial minicell derived from a eubacterial parent cell, wherein the minicell comprises a biologically active compound and displays an antibody or antibody derivative, wherein the biologically active compound is selected from the group consisting of a polypeptide, a small molecule, and a nucleic acid, and wherein the biologically active compound and the antibody or antibody derivative are exogenous to the parent cell and distinct from each other.

2 . The minicell of claim 1 , wherein the biologically active compound is a polypeptide.

3 . The minicell of claim 2 , wherein the polypeptide is a fusion protein.

4 . The minicell of claim 2 , wherein the polypeptide is a soluble polypeptide.

5 . The minicell of claim 2 , wherein the polypeptide is a protein toxin.

6 . The minicell of claim 1 , wherein the biologically active compound is a small molecule.

7 . The minicell of claim 6 , wherein the small molecule is a drug molecule.

8 . The minicell of claim 1 , wherein the biologically active compound is a nucleic acid.

9 . The minicell of claim 8 , wherein the nucleic acid comprises an antisense nucleic acid.

10 . The minicell of claim 8 , wherein the nucleic acid comprises a ribozyme.

11 . The minicell of claim 8 , wherein the nucleic acid comprises an aptamer.

12 . The minicell of claim 1 , wherein the minicell displays an antibody.

13 . The minicell of claim 1 , wherein the minicell displays an antibody derivative.

14 . A fully intact eubacterial minicell derived from a eubacterial parent cell, wherein the minicell comprises a biologically active compound and displays an antibody or antibody derivative, wherein the biologically active compound is a therapeutic polypeptide, and wherein the biologically active compound and the antibody or antibody derivative are exogenous to the parent cell and distinct from each other.

15 . The minicell of claim 14 , wherein the therapeutic polypeptide is a soluble polypeptide.

16 . The minicell of claim 14 , wherein the therapeutic polypeptide is a protein toxin.

17 . A fully intact eubacterial minicell derived from a eubacterial parent cell, wherein the minicell comprises a biologically active compound and displays an antibody or antibody derivative, wherein the biologically active compound is a therapeutic nucleic acid, and wherein the biologically active compound and the antibody or antibody derivative are exogenous to the parent cell and distinct from each other.

18 . The minicell of claim 17 , wherein the therapeutic nucleic acid comprises an antisense nucleic acid.

19 . The minicell of claim 17 , wherein the therapeutic nucleic acid comprises a ribozyme.

20 . The minicell of claim 17 , wherein the therapeutic nucleic acid comprises an aptamer.

Assignments (1)
SECURITY AGREEMENT Recorded Mar 21, 2013
From: VAXIION THERAPEUTICS INC.
To: WESTERN STATES INVESTMENT COMPANY, LLC
Reel/Frame 030062/0774 →